Gold Standard Diagnostics, a Eurofins Technologies company, announces the launch of a PCR test for the detection of monkeypox virus and orthopoxvirus

LUXEMBOURG, June 23, 2022–(BUSINESS WIRE)–Gold Standard Diagnostics Europe continues to respond to the threat posed by emerging infectious diseases by developing a new multiplex real-time PCR test to detect Monkeypox virus (Monkeypox infection) and to differentiate it from other orthopoxviruses.

Monkeypox virus is of significant concern given its recent spread, with more than 2,500 confirmed cases in 37 countries [1]. Particularly unusual, these cases have not been noted in travelers returning from the tropical rainforest regions of Central and West Africa – the usual area of ​​circulation of the virus. The US Centers for Disease Control and Prevention (CDC) has issued a level 2 alert for monkeypox virus.

Due to the current uncertainty surrounding the clinical implications of monkeypox virus, it is crucial to closely monitor its spread and provide reliable diagnostic solutions to identify it. This virus belongs to the genus Orthopoxvirus which includes pathogenic viruses such as smallpox (variola virus – eradicated), cowpox or buffalopox, which cause identical symptoms in infected patients.

Le real-time PCR multiplex test for monkeypox and Orthopox detection uses a general target for orthopoxviruses, and specific for monkeypox. It will be available, for research only, from the beginning of July. This product complements the set of tests developed by Gold Standard Diagnostics Europe in response to infectious diseases, such as the GSD NovaPrime and NovaType families of tests developed for the detection of the SARS-CoV-2 virus and the identification of its variants.


To learn more, please visit the Eurofins Technologies website.

About Eurofins Technologies – a fast-growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods

Built on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of state-of-the-art ELISA-based diagnostic technologies and instruments in the field of bioanalytical testing for the food industry. , animal nutrition, environment, animal health and clinical diagnostics.

About Eurofins – the world leader in bioanalysis

Eurofins analyzes in favor of life. With a workforce of 58,000 people, a network of 900 laboratories in 54 countries, Eurofins companies offer a portfolio of more than 200,000 analytical methods.

Eurofins shares are listed on Euronext Paris.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

View the source version on


For more information:
Rodrigo Berlie
[email protected]